Pfizer sees strong response for pediatric pneumonia vaccine in mid-stage trial
FatCamera/iStock via Getty Images
- Data from a phase 2 trial of Pfizer's (PFE) pediatric 25-valent pneumococcal conjugate vaccine PF-07872412 (25vPnC) showed that a four-dose series of the candidate provoked a robust immune response against all 25 serotypes.
- The shot also demonstrated safety and tolerability similar to four doses of Prevnar 20 (pneumococcal 20-valent conjugate vaccine).
- The study enrolled ~400 full-term infants with the primary objective comparing the safety of PF-07872412 to Prevnar 20. The four-dose series was given at 2, 4, 6, and 12 through 15 months of age.
- Results showed that local injection site reactions were mild to moderate, with those reactions and systemic events similar between those given PF-07872412 and Prevnar 20.
Recommended For You
Create Your Free Account to Keep Reading
Get the confidence to navigate an uncertain market with free breaking news and stock alerts.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.